Photo: Portos do Paraná
Anvisa, Brazil’s federal health regulatory body, has granted emergency authorization for the experimental Covid-19 treatment Regkirona, developed by Celltrion, a South Korean pharmaceutical company. Anvisa restricted the use of this intravenous antibody treatment exclusively to hospitals.
Manufacturers recommend treating patients who don’t need ventilators but face risks of a rapid progression of coronavirus infection.
Per the Korean Biomedical Review, Celltrion recently confirmed the ability of Regkirona to neutralize the Delta variant in animal tests.
The proportion of the Delta variant of the coronavirus identified in samples of SARS-CoV-2 — and registered on the international Gisaid platform, which gathers genomic data from 172 countries — has tripled in Brazil in the last four weeks.
Panama was once a part of Colombia. Its canal, a monumental engineering achievement of its…
The specialization trend among corporate board members It is not only a matter of perception:…
Panama will hold its presidential elections on Sunday, months after huge protests saw thousands descend…
The city of Rio de Janeiro estimates that a Madonna concert this Saturday on Copacabana…
Latin America’s trend of banning opposition candidates from elections has caught on in an ever-growing…
The São Paulo City Council on Thursday approved legislation authorizing Brazil’s largest city to sign…